Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus - A proposal from an expert panel
Copyright © 2023. Published by Elsevier B.V..
Anti-dsDNA autoantibodies are listed as one of the classification criteria for systemic lupus erythematosus (SLE) and are relatively effective indicators for monitoring disease activity and treatment response. Therefore, clinicians rely on them to diagnose and adjust medication and treatment strategies for SLE patients. However, the use of anti-dsDNA antibodies is not free from controversy. Part of this controversy stems from the fact that anti-dsDNA antibodies are found in several disorders, besides SLE. In addition to this, anti-dsDNA antibodies are a heterogeneous group of antibodies, and their determination still lacks proper standardization. Moreover, anti-dsDNA testing specificity and diagnostic performance change depending on the population under study. These and other issues result in inconsistency and encumber the clinical use of anti-dsDNA antibodies. A panel of medical laboratory and clinical experts on SLE discussed such issues based on their clinical experience in a first meeting, establishing a series of recommendations. The proceedings of this first meeting, plus an exhaustive review of the literature, were used to compose a paper draft. The panel subsequently discussed and refined this draft in a second meeting, the result of which is this paper. This document is relevant to clinical laboratories as it guides to improving diagnosis and monitoring of SLE. Simultaneously, it will help laboratories compile more informative reports, not limited to a mere number. It is also relevant to clinical doctors who wish to better understand laboratory methods so that they can do a more efficient, better-aimed laboratory test ordering.
| Errataetall: |
ErratumIn: Autoimmun Rev. 2024 Jan 17;23(2):103517. - PMID 38237216 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:22 |
|---|---|
| Enthalten in: |
Autoimmunity reviews - 22(2023), 12 vom: 22. Dez., Seite 103479 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Rojo, Ricardo [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Advisory board |
|---|
| Anmerkungen: |
Date Completed 04.12.2023 Date Revised 18.01.2024 published: Print-Electronic ErratumIn: Autoimmun Rev. 2024 Jan 17;23(2):103517. - PMID 38237216 Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.autrev.2023.103479 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364593636 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364593636 | ||
| 003 | DE-627 | ||
| 005 | 20240119231927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.autrev.2023.103479 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1264.xml |
| 035 | |a (DE-627)NLM364593636 | ||
| 035 | |a (NLM)37967782 | ||
| 035 | |a (PII)S1568-9972(23)00213-6 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Rojo, Ricardo |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recommendations for the use of anti-dsDNA autoantibodies in the diagnosis and follow-up of systemic lupus erythematosus - A proposal from an expert panel |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 04.12.2023 | ||
| 500 | |a Date Revised 18.01.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ErratumIn: Autoimmun Rev. 2024 Jan 17;23(2):103517. - PMID 38237216 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier B.V. | ||
| 520 | |a Anti-dsDNA autoantibodies are listed as one of the classification criteria for systemic lupus erythematosus (SLE) and are relatively effective indicators for monitoring disease activity and treatment response. Therefore, clinicians rely on them to diagnose and adjust medication and treatment strategies for SLE patients. However, the use of anti-dsDNA antibodies is not free from controversy. Part of this controversy stems from the fact that anti-dsDNA antibodies are found in several disorders, besides SLE. In addition to this, anti-dsDNA antibodies are a heterogeneous group of antibodies, and their determination still lacks proper standardization. Moreover, anti-dsDNA testing specificity and diagnostic performance change depending on the population under study. These and other issues result in inconsistency and encumber the clinical use of anti-dsDNA antibodies. A panel of medical laboratory and clinical experts on SLE discussed such issues based on their clinical experience in a first meeting, establishing a series of recommendations. The proceedings of this first meeting, plus an exhaustive review of the literature, were used to compose a paper draft. The panel subsequently discussed and refined this draft in a second meeting, the result of which is this paper. This document is relevant to clinical laboratories as it guides to improving diagnosis and monitoring of SLE. Simultaneously, it will help laboratories compile more informative reports, not limited to a mere number. It is also relevant to clinical doctors who wish to better understand laboratory methods so that they can do a more efficient, better-aimed laboratory test ordering | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Advisory board | |
| 650 | 4 | |a Anti-dsDNA autoantibodies | |
| 650 | 4 | |a Best practices | |
| 650 | 4 | |a Diagnosis | |
| 650 | 4 | |a Follow-up | |
| 650 | 4 | |a Systemic lupus erythematosus | |
| 650 | 4 | |a Testing | |
| 650 | 7 | |a anti-dsDNA autoantibody |2 NLM | |
| 650 | 7 | |a Autoantibodies |2 NLM | |
| 650 | 7 | |a Antibodies, Antinuclear |2 NLM | |
| 700 | 1 | |a Calvo Alén, Jaime |e verfasserin |4 aut | |
| 700 | 1 | |a Prada, Álvaro |e verfasserin |4 aut | |
| 700 | 1 | |a Valor, Santiago |e verfasserin |4 aut | |
| 700 | 1 | |a Roy, Garbiñe |e verfasserin |4 aut | |
| 700 | 1 | |a López-Hoyos, Marcos |e verfasserin |4 aut | |
| 700 | 1 | |a Cervera, Ricard |e verfasserin |4 aut | |
| 700 | 1 | |a Sánchez Mateos, Paloma |e verfasserin |4 aut | |
| 700 | 1 | |a Jurado Roger, Aurora |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Autoimmunity reviews |d 2002 |g 22(2023), 12 vom: 22. Dez., Seite 103479 |w (DE-627)NLM126096996 |x 1873-0183 |7 nnns |
| 773 | 1 | 8 | |g volume:22 |g year:2023 |g number:12 |g day:22 |g month:12 |g pages:103479 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.autrev.2023.103479 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 22 |j 2023 |e 12 |b 22 |c 12 |h 103479 | ||